Nelivaptan

Evidence outlook · lead readout

NCT00358631 · Depressive Disorder

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT00358631: The study randomized 319 participants and masked both participants and investigators, using change in the clinical HAM-D depression score as its primary endpoint. However, no results are posted, and the registry does not clearly identify the comparator arms or report whether the primary endpoint was met.

Caveat: figures are the trial's original primary result as reproduced in a later reanalysis publication; the cited source's own analysis applies a different (bimodal-response) model.